PROMPT-IBDEarly Infliximab Optimization for IBD Patients Using Bayesian Model

Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis, is a long-lasting condition that often requires costly treatments like biologic therapies. Anti-TNF medications, such as infliximab, are effective but not all patients respond well to them initially or over time. In Chile, these medications are provided by a national program. The study aims to explore if adjusting infliximab doses early, using a special monitoring method called therapeutic drug monitoring (TDM) and a Bayesian model, can help more patients achieve the right drug levels, reduce the chance of the body reacting against the drug, and increase the likelihood of the disease going into remission. Participants in this study are adults in Chile with moderate-to-severe IBD that hasn't responded to standard steroid treatments. They will be randomly divided into two groups. One group will have their infliximab doses adjusted using a dashboard-guided method with regular monitoring, while the other group will have doses adjusted based on standard clinical assessments. Researchers will check drug levels and immune reactions at various points, specifically at weeks 14, 26, and 52. The study aims to see if the first method leads to better drug levels and fewer adverse reactions, ultimately improving the patients' condition.